Pan-Bcl-2 family inhibition or Bcl-xL–specific inhibition combined with radiotherapy in vivo led to significantly reduced tumor sizes and delayed tumor growth in cell line and PDX TNBC models (Fig. 4). The gene discussed is BCL2L1; the disease is neoplasm.